BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a
biotechnology company focused on immuno-oncology, recently reported the
impending clinical use of a novel frozen formulation of the company’s lead
cancer drug candidate, Bria-IMT. The new, easy-to-use formulation can be
transported more simply to distant locations. An article discussing the company
reads, “The company’s frozen formulation allows for the storage of
cryopreserved, ready-to-inject Bria-IMT for cold-chain overnight transport to
clinical sites where it will be thawed prior to injection in patients. This
unique formulation of Bria-IMT has also shown improved potency compared to the
old formulation in vitro. Long term, this novel, frozen formulation is expected
to carry reduced per-dose costs compared to the old formulation, the company
stated in a news release (http://ibn.fm/qHd1W).
Bria-IMT activates the immune system to destroy cancer cells in a way that’s
believed to be both unique and more effective than other, similar approaches.
The frozen formulation will also be applicable to Bria-OTS, BriaCell’s
personalized off-the-shelf immunotherapy, which is being developed.”
To view the full article, visit http://ibn.fm/XD8Ej
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company
developing targeted and safe approaches for the management of cancer. BriaCell
is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead
candidate, in a combination study with pembrolizumab [Keytruda; manufactured by
Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers
Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026.
BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy
for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized
to match the patient without the need for personalized manufacturing. Bria-OTS,
which is expected to cover over 90 percent of the patient population, is
designed to produce a potent and selective immune response against the cancer
of each patient while eliminating the time, expense and complex manufacturing
logistics associated with other personalized immunotherapies. For more
information, visit the company’s website at www.BriaCell.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment